Skip to main content
GLP-1 receptor agonist

Semaglutide Ozempic® / Wegovy®

The SHIKARI® Semaglutide portfolio provides quantitative anti-semaglutide antibody analysis with an IFU-defined confirmation workflow.

1
SHIKARI® Kit
96
Tests per kit
1
Analytical Domain
RUO
Research Use Only
Official Matriks Biotek Semaglutide product visual
TRACE & CATCH · SEMAGLUTIDE
Scientific Background

Why Semaglutide is relevant to biological-drug monitoring research

Semaglutide has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗

Mechanism

Molecular Target & Structure

Semaglutide is a long-acting GLP-1 receptor agonist peptide analogue that enhances glucose-dependent insulin secretion, suppresses glucagon and slows gastric emptying. Source ↗

Indications

Approved Indications

For the Ozempic®-family product context relevant to this page, EMA authorisation is for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, used alone or with other glucose-lowering medicines according to the label. EMA source ↗

Regulatory PK Context

Weekly Steady-State Exposure

FDA pharmacokinetic data show approximately dose-proportional steady-state serum concentrations under weekly subcutaneous dosing:

0.5 mg weekly · mean steady-state~65 ng/mL
1 mg weekly · mean steady-state~123 ng/mL
2 mg weekly · mean steady-state~222 ng/mL

Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.

SHIKARI® Kit Portfolio

One verified Semaglutide research assay

SHIKARI® S-ATSEM kit, REF SEM-QNS-OZE
Quantitative ADA Kit
SHIKARI® S-ATSEM
Quantitative Antibodies to Semaglutide (Ozempic®) ELISA with Confirmation
REF: SEM-QNS-OZE

Quantitative ELISA for anti-semaglutide antibodies with an assay-specific confirmation workflow.

Representative Standard Curve
SHIKARI® S-ATSEM representative standard curve for illustrative purposes only
96Tests/kit
2–8°CStorage
10–30°CShipment
Quantitative ADASerum / Plasma6-month shelf life
Technical Reference

Verified Specifications at a Glance

KitREFModeAnalyteSampleVolumeTimeAnalytical outputTestsShelf lifeStorageShipping
SHIKARI® S-ATSEMSEM-QNS-OZEQuantitativeAnti-semaglutide antibodiesHuman serum / plasma5 µL140 minLOD 5 ng/mL; LOQ 1.56 µg/mL966 months2–8°C10–30°C

Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.

Kit Selection Guide

Match the assay to the research question

01
Quantify anti-semaglutide antibodies
Use SEM-QNS-OZE for a quantitative ADA result.
02
Use confirmation controls
Use SEM-QNS-OZE with the IFU-defined confirmation-reagent workflow.
03
Do not use as a drug-level assay
Use SEM-QNS-OZE because this REF measures antibodies to semaglutide, not semaglutide concentration.
Scientific Literature

Semaglutide Literature and Product-Use Records

Technical Support & Quotations

Planning a Semaglutide research study?

Matrix Biotek can help identify the appropriate Semaglutide assay and prepare regional quotation and delivery information.

Quotation Request

Review your quote list

Your quotation request is sent directly to Matrix Biotek. A confirmation copy will be sent to your institutional email. No payment is taken online. Current regional pricing, availability and delivery information will be provided in the quotation.

Technical Support